Aclaris Therapeutics, Inc.
Common Stock · USD · NASDAQ
Price
$4.65
Cap
—
Earnings
—
30d Trend
+8.4%
71% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 49×Macro 0.99 (−1%)=49
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
6-9 month momentum thesis — strong trend with confirmation
BRAIN47'S ASSESSMENT
I rate Aclaris Therapeutics, Inc. at 49/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 69/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
+2.2%
3 MONTHS
+59.2%
12 MONTHS
+213.0%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
6-9 month momentum thesis — strong trend with confirmation. Momentum (69) and Technical (55) are the primary strengths. I note that fundamentals is the weakest area at 15/100 — this warrants monitoring. Historical volatility is elevated at 71%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.